| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.083 | 0.3 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.053 | 0.4 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |